VEGFA and age-related macular degeneration: In the MARINA (Minimally Classic/Occult Trial of the Anti-VEGF Antibody Ranibizumab in the Treatment of Neovascular AMD) trial, patients with either “minimally classic” or “occult” angiographic leakage patterns were randomized to receive monthly injections of intravitreal ranibizumab (0.3 mg or 0.5 mg) or monthly sham injections [80].